Zdrowie i gospodarka · 03/04/2024

FDA Releases Draft Guidance on Data Integrity for In Vivo Bioavailability and Bioequivalence Studies

The FDA is releasing a draft guidance to help industry achieve and maintain data integrity for bioavailability and bioequivalence studies, which are crucial for new drug applications and biologic license applications.